Cómo citar
Resumen
N.A
Citas
European Medicines Agency. EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373) [Internet]. 2021. Available from: https://www.ema.europa.eu/en/news/ema-starts-rolling-reviewnovavaxs-covid-19-vaccine-nvx-cov2373
Government of Canada. Drug and vaccine authorizations for COVID-19: List of applications received [Internet]. Available from: https://www.canada.ca/en/health-canada/services/drugs-healthproducts/covid19-industry/drugs-vaccines-treatments/authorization/applications.html
Novavax. Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization [Internet]. 2021. Available from: https://ir.novavax.com/news-releases/newsrelease-details/novavax-announces-start-rolling-review-multiple-regulatory
Novavax. Novavax COVID-19 Vaccine Demonstrates 89.3 % Efficacy in UK Phase 3 Trial. 2021;(August 2020):2–4. Available from: https://ir.novavax.com/node/15506/pdf
Copyright © 2020 MU and EPIA rights reserved. GRADEpro software [Internet]. 2020. Available from:
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 Trial of a SARS-CoV-2
Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med [Internet]. 2020 Sep 2;383(24):2320–32. Available from: https://doi.org/10.1056/NEJMoa2026920